【Asset for Licensing】CCR8-targeting mAb in clinical stage for solid tumors

Asset: Highly selective CCR8-targeting IgG1 monoclonal antibody
Development Stage: Clinical stage
Indication: Advanced solid tumors
Key Asset Highlights:
（1）Features high selectivity for CCR8, a key biomarker specifically enriched on tumor-infiltrating regulatory T cells (Tregs), enabling precise targeting of the tumor immunosuppressive microenvironment.
（2）Exerts unique anti-tumor mechanisms by bridging CCR8 on Treg cells and FcγR on NK cells, efficiently depleting intratumoral immunosuppressive Tregs and reversing tumor immune tolerance.
（3）Delivers potent single-agent anti-tumor activity with robust tumor growth inhibition observed in preclinical solid tumor models, demonstrating promising monotherapy therapeutic potential.
（4）Exhibits prominent synergistic anti-tumor efficacy in combination with PD-(L)1 immune checkpoint inhibitors, effectively unlocking synergistic immunotherapy effects and broadening clinical treatment benefits.
（5）Demonstrates favorable safety and tolerability profiles in ongoing clinical trials, with preliminary clinical anti-tumor efficacy validated in advanced solid tumor patients.
Supported by a comprehensive intellectual property layout, securing exclusive and stable global development and commercialization rights for immunotherapy applications across solid tumors.

If you are interested in these opportunities, please feel free to contact DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.